Position in URGN
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$4,281,433
-$745,014 QoQ
Shares Held
238,122
+10.9% QoQ
Ownership
0.489%
of shares outstanding
% of Portfolio
0.89%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Privium Fund Management B.V. holds $142,100,239 across 32 Biotechnology names. URGN ranks #11 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
366,936 | $23,006,887 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
290,024 | $21,777,902 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
58,729 | $9,926,375 | |
| 4 | PRQR |
ProQR Therapeutics N.V.
|
5,467,149 | $8,856,781 | |
| 5 | QURE |
uniQure N.V.
|
486,520 | $7,954,602 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
364,802 | $7,642,601 | |
| 7 | ARQT |
Arcutis Biotherapeutics, Inc.
|
320,972 | $7,562,100 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
92,305 | $5,214,309 |
All Filings in URGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,281,433 | 238,122 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $5,026,447 | 214,622 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $3,922,608 | 196,622 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $1,474,421 | 107,622 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $1,190,299 | 107,622 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $294,909 | 27,691 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||